SCHEMBL1038006

SCHEMBL1038006

Cc1noc(NC(=O)N2CCC(=Cc3cccc(OCC4CCCCO4)c3)CC2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.42
MAPT P10636 3/20 0.42
CYP3A4 P08684 4/20 0.41
CYP2D6 P10635 4/20 0.41
ALDH1A1 P00352 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
RAB9A P51151 7/20 0.39
NPC1 O15118 6/20 0.39
TDP1 Q9NUW8 1/20 0.39
GRM5 P41594 1/20 0.39
SCD O00767 1/20 0.38
LMNA P02545 2/20 0.38
FAAH O00519 1/20 0.38
GABRA1 P14867 1/20 0.38
ADRA2C P18825 1/20 0.38
CNR1 P21554 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1036429 0.91 CYP3A4 (0.42) CYP3A4CYP2D6ALDH1A1LMNAFAAH
SCHEMBL4384599 0.85 CYP3A4 (0.58) SMN1; SMN2MAPTCYP3A4CYP2D6ALDH1A1
SCHEMBL1036041 0.84 CYP3A4 (0.44) CYP3A4CYP2D6SCDFAAHGABRA1
SCHEMBL1033156 0.84 CYP3A4 (0.40) SMN1; SMN2CYP3A4CYP2D6ALDH1A1LMNA
SCHEMBL1037033 0.84 CYP3A4 (0.42) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1036377 0.83 CYP2D6 (0.44) SMN1; SMN2MAPTCYP3A4CYP2D6FAAH
SCHEMBL1036375 0.83 CYP3A4 (0.44) SMN1; SMN2MAPTCYP3A4CYP2D6ALDH1A1
SCHEMBL1040115 0.83 FAAH (0.56) SMN1; SMN2MAPTCYP3A4CYP2D6RAB9A
SCHEMBL6526889 0.82 CYP3A4 (0.39) SMN1; SMN2MAPTCYP3A4CYP2D6ALDH1A1
SCHEMBL1037574 0.82 CYP3A4 (0.57) SMN1; SMN2MAPTCYP3A4CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053982-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2011-03-03 US claimed
EP-2276738-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS Pfizer Inc. (US) 2011-01-26 EP claimed
WO-2009127943-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2009-10-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053982-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS FAAH, FAAH2, CNR2 SMN1; SMN2 3102/4885MAPT 3493/4885CYP3A4 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.